HER2-Low Breast Cancer: Pathological and Clinical Landscape

doi:10.1200/JCO.19.02488

Review

. 2020 Jun 10;38(17):1951-1962.

doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24.

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Paolo Tarantino^{1

2}, Erika Hamilton³, Sara M Tolaney⁴, Javier Cortes^{5

6}, Stefania Morganti^{1

2}, Emanuela Ferraro^{1

2}, Antonio Marra^{1

2}, Giulia Viale^{1

2}, Dario Trapani^{1

2}, Fatima Cardoso⁷, Frédérique Penault-Llorca^{8

9}, Giuseppe Viale^{1

2}, Fabrice Andrè¹⁰, Giuseppe Curigliano^{1

2}

Affiliations

¹ European Institute of Oncology IRCCS, Milan, Italy.
² University of Milan, Milan, Italy.
³ Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
⁴ Dana-Farber Cancer Institute, Boston, MA.
⁵ IOB Institute of Oncology, Quiron Group, Madrid and Barcelona, Spain.
⁶ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
⁷ Breast Unit Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
⁸ Jean Perrin Comprehensive Cancer Center, Department of Pathology and Tumor Biology, Centre Jean Perrin, Clermont-Ferrand, France.
⁹ UMR INSERM 1240 IMoST, Université Clermont Auvergne, Villejuif, France.
¹⁰ Department of Medical Oncology, Gustave Roussy, Villejuif, France.

PMID: 32330069
DOI: 10.1200/JCO.19.02488

Review

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Paolo Tarantino et al. J Clin Oncol. 2020.

. 2020 Jun 10;38(17):1951-1962.

doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24.

Authors

Affiliations

¹ European Institute of Oncology IRCCS, Milan, Italy.
² University of Milan, Milan, Italy.
³ Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
⁴ Dana-Farber Cancer Institute, Boston, MA.
⁵ IOB Institute of Oncology, Quiron Group, Madrid and Barcelona, Spain.
⁶ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
⁷ Breast Unit Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
⁸ Jean Perrin Comprehensive Cancer Center, Department of Pathology and Tumor Biology, Centre Jean Perrin, Clermont-Ferrand, France.
⁹ UMR INSERM 1240 IMoST, Université Clermont Auvergne, Villejuif, France.
¹⁰ Department of Medical Oncology, Gustave Roussy, Villejuif, France.

PMID: 32330069
DOI: 10.1200/JCO.19.02488

No abstract available

PubMed Disclaimer

Cited by

Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h + HER2- breast cancer: a retrospective analysis.
Kook Y, Lee YJ, Chu C, Jang JS, Baek SH, Bae SJ, Cha YJ, Gong G, Jeong J, Lee SB, Ahn SG. Kook Y, et al. Breast Cancer Res. 2024 Nov 6;26(1):154. doi: 10.1186/s13058-024-01911-9. Breast Cancer Res. 2024. PMID: 39506855
Current status and challenges in HER2 IHC assessment: scoring survey results in Japan.
Sakatani T, Tsuda H, Yoshida M, Honma N, Masuda S, Osako T, Hayashi A, Jara-Lazaro AR, Horii R. Sakatani T, et al. Breast Cancer Res Treat. 2024 Nov 4. doi: 10.1007/s10549-024-07532-2. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39496910
Ultrasound Radiomics for the Prediction of Breast Cancers with HER2-Zero, -Low, and -Positive Status: A Dual-Center Study.
Yin Y, Mo S, Li G, Wu H, Hu J, Zheng J, Liu Q, Wang M, Xu J, Huang Z, Tian H, Dong F. Yin Y, et al. Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241292668. doi: 10.1177/15330338241292668. Technol Cancer Res Treat. 2024. PMID: 39470030 Free PMC article.
The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer.
Şen GA, Aydın E, Guliyev M, Öztaş NŞ, Değerli E, Demirci NS, Turna ZH, Demirelli FH. Şen GA, et al. BMC Cancer. 2024 Oct 24;24(1):1311. doi: 10.1186/s12885-024-13064-1. BMC Cancer. 2024. PMID: 39448928 Free PMC article.
Improved Prognosis in HER2-Low Breast Cancer Patients with Reduced Ki67 Index After Neoadjuvant Chemotherapy: A Multi-Center Retrospective Study.
Huang M, Jin Y, Wang M, Song Q, Fan Y, Zhang Y, Tian C, Zhang C, Liu S. Huang M, et al. Breast Cancer (Dove Med Press). 2024 Oct 10;16:667-678. doi: 10.2147/BCTT.S478110. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 39403364 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Affiliations

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Authors

Affiliations

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous